SCHEMBL2111969

SCHEMBL2111969

Oc1c[nH]c2ncccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.60
GPR84 Q9NQS5 1/20 0.58
LRRK2 Q5S007 1/20 0.55
KMT2A Q03164 1/20 0.55
CDC7 O00311 2/20 0.54
MAP2K1 Q02750 1/20 0.53
MET P08581 2/20 0.50
CAMKK2 Q96RR4 2/20 0.49
TGFBR1 P36897 3/20 0.49
PDPK1 O15530 2/20 0.49
IKBKE Q14164 2/20 0.49
CCNB2 O95067 1/20 0.47
CDK1 P06493 1/20 0.47
RET P07949 1/20 0.47
CCNB1 P14635 1/20 0.47
CCNB3 Q8WWL7 1/20 0.47
MTNR1A P48039 1/20 0.46
CDK2 P24941 2/20 0.46
ROCK2 O75116 1/20 0.46
MAP4K4 O95819 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL2489398 0.89 MAP2K1 (0.56) AXLGPR84LRRK2KMT2ACDC7
Ethoxycarbonyl Group SCHEMBL27574859 0.81 KMT2A (0.49) AXLGPR84LRRK2KMT2ACDC7
SCHEMBL12657321 0.79 AXL (0.60) AXLGPR84LRRK2KMT2ACDC7
SCHEMBL5618155 0.78 TGFBR1 (0.71) AXLGPR84LRRK2KMT2ACDC7
SCHEMBL857148 0.78 TGFBR1 (0.57) AXLGPR84CDC7CAMKK2TGFBR1
SCHEMBL2217980 0.76 GPR84 (0.76) AXLGPR84LRRK2KMT2AMAP2K1
SCHEMBL410624 0.75 AXL (1.00) AXLGPR84LRRK2KMT2ACDC7
SCHEMBL12188 0.75 AXL (0.60) AXLGPR84LRRK2KMT2ACDC7
SCHEMBL368676 0.75 AXL (0.60) AXLGPR84LRRK2KMT2ACDC7
SCHEMBL12605500 0.75 AXL (0.60) AXLGPR84LRRK2KMT2ACDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190263800-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2019-08-29 US disclosed
EP-2379549-B1 7-AZAINDIRUBINS, 7'-AZAINDIRUBINS, 7-7'-DIAZAINDIRUBIN AND THE CORRESPONDING 3'-OXIME ETHER DERIVATES: PRODUCTION THEREOF, THEIR PRODUCTION AND USE AS A MEDICAMENT EISENBRAND GERHARD (DE) 2016-09-21 EP disclosed
US-8158647-B2 Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators SGX PHARMACEUTICALS, INC. (US) 2012-04-17 US disclosed
EP-2379549-A1 7-AZAINDIRUBINS, 7'AZAINDIRUBINS, 7,7'-DIAZAINDIRUBINS AND THE CORRESPONDING 3'-OXIME ETHER DERIVATIVES THEREOF, THEIR PRODUCTION AND USE AS A MEDICAMENT Eisenbrand, Gerhard (DE) 2011-10-26 EP disclosed
CN-101778629-A Substituted pyrrolopyridine and pyrazolopyridine compounds useful as kinase modulators SGX PHARMACEUTICALS INC 2010-07-14 CN disclosed
WO-2010072399-A1 7-AZAINDIRUBINS, 7'AZAINDIRUBINS, 7,7'-DIAZAINDIRUBINS AND THE CORRESPONDING 3'-OXIME ETHER DERIVATIVES THEREOF, THEIR PRODUCTION AND USE AS A MEDICAMENT EISENBRAND GERHARD (DE) 2010-07-01 WO disclosed
EP-2199292-A1 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament Technische Universität Kaiserlautern (DE) 2010-06-23 EP disclosed
US-20090005356-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005356-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS PDXK, MAP3K4, PDPK1 AXL 599/4885GPR84 492/4885LRRK2 1040/4885
US-20190263800-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 AXL 319/4885GPR84 228/4885LRRK2 3185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.